---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-23-000657"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:43:32.777868+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical Q1 net loss $6.3M; maintains IND filing timeline for NPM-119

## Summary
- Cash $38.1M at March 31, 2023, down from $45.1M; sufficient to fund operations into H2 2024.
- R&D expense $4.0M (+48% YoY); operating expenses $6.6M (+69% YoY) driven by Second Sight acquisition costs.
- Net loss $6.3M vs $3.9M in Q1 2022; increase due to $2.7M higher operating expenses.
- Plans to file NPM-119 IND with FDA by mid-2023; if cleared, initiate LIBERATE-1 trial in Q3 2023 with top-line data in H1 2024.
- Expects to complete Cortigent IPO in Q3 2023; Vivani to retain control after offering.

## SEC filing metadata
- accession: 0001753926-23-000657
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392623000657/0001753926-23-000657-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392623000657/g083544_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-23-000657
- JSON: https://secwatch.observer/filing/0001753926-23-000657.json
- Plain text: https://secwatch.observer/filing/0001753926-23-000657.txt

## Key facts
- Earnings Releases
  Vivani Medical, Inc. reported first quarter ended March 31, 2023 results: net income $6.3 million.
  - Period: first quarter ended March 31, 2023
  - Net income: $6.3 million
  - Result: reported results
  source text: Net Loss: The net loss was $6.3 million as compared to $3.9 million for the three-months ended March 31, 2023, and 2022, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1266806/000175392623000657/0001753926-23-000657-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.